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This review of practical and theoretical advances in an-
tiarrhythmic drug therapy consists of four parts. Part
1, on clinical applications, compares the approaches to
treatment 25 years ago with those of today, examines
the current status of antiarrhythmic drugs used 25 years
ago, reports on drugs approved for clinical use during
the past 25 years, reviews new experimental drugs and
suggests an approach to classificationof antiarrhythmic
drugs. Part 2 summarizes the contributions of cellular
electrophysiology to the understanding of drug action,
with emphasis on the drug-induced block of the voltage-
In assuming the responsibility for reviewing the pharma-
cologic treatment of cardiac arrhythmias during the past 25
years, I have not overlooked the severe shortcomings of this
undertaking. The constraint of space is a minor impediment
compared with the limitations of personal knowledge and
the lack of experience in many areas encompassed by this
review . These limitations also may have detracted from the
accuracy of the chronology and the priorities of different
discoveries and advancements . With regard to the choice
of references, I apologize in advance to those contempo-
raries whose work 1 have inadvertently omitted, misrepre-
sented or insufficiently emphasized. My consolation is that
no historical perspective can be truly exhaustive or entirely
free of personal bias , and my excuse for reviewing this topic
is that 1 have been an interested witness to the described
developments for more than 25 years.
Clinical Applications
25 Years Ago and Today
Approach to therapy in 1956. In the 1956 edition of
Friedberg ' s Diseases of the Heart (1), the overall approach
to antiarrhythmic therapy was similar in principle to con-
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and time-dependent properties of the rapid sodiumchan-
nel. The subsequent section contains a brief discussion
of the impact made by the new knowledge and the new
diagnostic technology on the contemporary practices.
The main conclusions are 1) that the more rational ap-
proach to treatment has benefited proportionately more
patients with supraventricular than with ventricular ar-
rhythmias, and 2) that new advances have made it pos-
sible to design successful treatments for certain patients
with problems that could bot be resolved in the past.
temporary practices. Premature beats were usually asymp-
tomatic and required no treatment. Reassurance, prudent
life style and elimination of smoking, alcohol and coffee
had precedence over drug therapy. In Friedberg 's experi-
ence , the most effect ive drug for treatment and prevention
of symptomatic ventricular arrhythmias was procainamide
in doses of 0.25 to 1.0 g four times daily; second on the
list was quinidine sulfate in doses of 0.3 to 0.6 g, three to
six times daily. Occasionally ventricular premature beats
were abolished with digitalis, and potassium salts were chiefly
used to treat digitalis toxicity . Lanatoside (Cedilanid) and
phenylephrine hydrochloride (Neo-Synephrine) were the most
effectiv e drugs for paroxysmal supraventricular tachycardia
resistant to carotid sinus pressure; digitalis and quinidine
were used to prevent attacks of paroxysmal supraventricular
tachycardia . Digital is was the drug of choice for treatment
of established atrial fibrillation and, together with quinid ine
and occasionally procainamide , was used to restore sinus
rhythm and prevent recurrent attacks of atrial flutter or fi-
brillation. Determination of blood level concentrations of
quinidine was helpful in guiding therapy, although quinidine
toxicity was known to occur in the presence of therapeutic
blood levels. For emergenc y treatment of ventricular tachy-
cardia, procainamide administered intravenousl y or intra-
muscularly was the drug of choice. Procainamide or quin-
idine was admini stered orally to prevent ventricular
tachycardia or syncopal attacks caused by ventricular
fibrillation.
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Electrical defibrillation had already been tried on at least
one occasion. For cardiac arrest due to sinoatrial (SA) or
atrioventricular (AV) block, pacemakers were not yet avail-
able, and the recommended drugs included isoproterenol
administered sublingually , ephedrine and atropine sulfate.
Although the supraventricular tachycardia in patients with
the Wolff-Parkinson-White syndrome was treated in the same
manner as in those without this syndrome, Friedberg (I)
cautioned that digitalis was not effective in the presence of
paroxysmal atrial fibrillation and wide QRS tachycardia. He
suggested that such attacks should be treated with quinidine,
which "tends to suppress the anomalous mechanism."
1982 approach to therapy. In the latest edition of the
comprehensive multiauthor cardiology textbook edited by
Hurst (2), temporary and permanent pacemakers, electrical
defibrillation, direct current cardioversion and surgical pro-
cedures are prominent features in the treatment of cardiac
arrhythmias. Drug treatment of supraventricular arrhythmias
has changed considerably since 1956. Verapamil or pro-
pranolol is now being administered intravenously to slow the
ventricular rate if patients poorly tolerate atrial fibrillation
or atrial flutter. Verapamil is the drug of choice to terminate
paroxysmal supraventricular tachycardias. In addition to di-
goxin, verapamil and beta-receptor blocking drugs are being
used orally to prevent supraventricular arrhythmias or to
slow the ventricular rate in patients with these arrhythmias.
Intravenous lidocaine is the drug of choice for interrupting
ventricular tachycardia, but procainamide may be used if
conversion to sinus rhythm is not obtained. For chronic
ventricular tachycardia the therapeutic recommendation may
be guided by the results of electrophysiologic testing. Quin-
idine, disopyramide, propranolol and procainamide are the
most commonly effective drugs. Phenytoin may occasion-
ally be helpful, and amiodarone appears to be the most
useful agent for arrhythmias that are refractory to the ap-
proved drugs. For digitalis toxicity, correction of hypoka-
lemia is frequently the best treatment, although arrhythmias
may be treated effectively with phenytoin or propranolol.
In patients with the Wolff-Parkinson-White syndrome and
recurrent atrial flutter or fibrillation, the most effective drug
appears to be amiodarone; if it is not available, quinidine
and disopyramide may accomplish the desired result (2).
Therapy of ventricular arrhythmias. Perhaps the least
progress has occurred in the treatment of ventricular ar-
rhythmias. To document this statement, I have chosen to
review my own recommendations made in 1965 (3). For
treatment of ventricular ectopic complexes in patients not
receiving digitalis, I recommended a search for precipitating
causes; if none was found, I tried to reduce anxiety by means
of reassurance and perhaps mild sedation. When suppressive
therapy was indicated, I suggested trying digitalis first. Al-
though this drug is frequently less effective than quinidine
or procainamide, patients responding favorably to digitalis
therapy are spared the risk, cost and inconvenience asso-
ciated with the prolonged intake of antiarrhythmic drugs.
In patients not responding to digitalis, the most common
drugs of choice were quinidine in doses of 0.2 to 0.4 g. and
procainamide, 0.25 to 0.5 g, each given 4 to 6 times daily.
A long-acting quinidine gluconate in a dose of 0.6 g every
12 hours was also available. I also recommended against
continuing antiarrhythmic therapy indefinitely without pe-
riodic attempts to reduce the dose or discontinue adminis-
tration of the drug. I mentioned that after acute myocardial
infarction, quinidine therapy is instituted by many cardiol-
ogists to prevent serious ventricular tachyarrhythmias, but
the merits of this therapy had not yet been adequately doc-
umented. Oral administration of potassium salts was rec-
ommended in patients with hypokalemia or potassium de-
pletion. At that time, in patients receiving digitalis who had
ventricular arrhythmias, I used the acetylstrophanthidin tol-
erance test in doubtful cases. To prevent recurring ventric-
ular tachycardia in the absence of AV conduction distur-
bances, I suggested avoiding the precipitating causes and
treating the underlying heart disease as the first approach,
using quinidine or procainamide orally with or without dig-
italis. For interruption of ventricular tachycardia, electrical
countershock and lidocaine were already available (4,5) and
use of intravenous quinidine had been abandoned.
It appears that today, despite the increasing use of ex-
ercise tests, ambulatory electrocardiographic monitoring,
drug blood level testing and the availability of complex
electrophysiologic studies, the recommendations made in
1965 still apply to the vast majority of patients with ven-
tricular arrhythmias. In their 1982 textbook, the authors (2)
admit that the accurate identification of patients most likely
to benefit from antiarrhythmic therapy remains unsatisfac-
tory and that quinidine is perhaps the drug of choice for
treatment of ventricular premature beats, although disopyr-
amide. propranolol and sustained-release procainamide are
good alternatives. The apparent standstill in the progress of
antiarrhythmic therapy for ventricular arrhythmias con-
strasts with a gratifying evolution of the therapeutic ap-
proach to patients with paroxysmal supraventricular tachy-
cardias, paroxysmal or chronic atrial fibrillation and flutter
and to the rare episodes of dangerous atrial tachyarrhythmias
in patients with the Wolff-Parkinson-White syndrome and
a short refractory period of the bypass tract. For these pa-
tients, the availability of beta-receptor blocking agents, slow
channel blocking drugs or amiodarone has substantially
broadened the therapeutic options for lessening disability
and improving the quality of life.
What Happened to the Antiarrhythmic Drugs Used
25 Years Ago?
Digitalis. The digitalis-induced shortening of the re-
fractory period in the atrium and ventricles has been con-
firmed in human subjects (6). Some cardiologists still use
digitalis in combination with antiarrhythmic drugs to prevent
serious ventricular tachyarrhythmias (7). From the results
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of the acetylstrophanthidin tolerance test, Lown et al. (7)
concluded that the glycosides significantly reduced the fre-
quency or the severity of ventricular ectopic activity in 46%
of patients (65 of 142) and completely suppressed ventric-
ular arrhythmia in 21% of subjects. In the past, such effects
had been attributed to the drug's positive inotropic action
which resulted in improved perfusion of the depressed and
"arrhythmogenic" myocardium. However, the absence of
congestive heart failure in many patients suggested to Lown
et al. (7) that the antiarrhythmic effect of digitalis might
have resulted from a lessening of adrenergic tone caused by
vagal action of glycosides. This explanation implies an in-
direct antiarrhythmic effect because digitalis itself has no
apparent antiadrenergic effect on the ventricle (8).
The ability to measure serum digoxin concentrations (9)
has contributed to reduction of digoxin toxicity when this
measurement is used routinely in the hospital (10). How-
ever, it has not been established whether the knowledge of
serum concentrations is diagnostically more useful than
knowledge of the digitalis dosage, renal function, serum
potassium and cardiac status (11). Also, the knowledge of
serum digoxin concentrations is not very helpful in control
of the ventricular rate in patients with atrial fibrillation (12).
It appears that decision making based on the results of di-
goxin concentration measurements results in a lesser prev-
alence of toxicity but a greater number of patients receiving
inadequate doses of the drug. In patients with chronic atrial
fibrillation or flutter the inadequate dosage can usually be
corrected by adding a beta-receptor blocking drug or
verapamil.
Other important developments include better understand-
ing of digitalis toxicity due to the discovery of delayed
afterdepolarizations (see References) and the availability of
digoxin-specific antibodies for treatment of severe digoxin
intoxication (13). Digoxin is less uniformly bioavailable
than the better absorbed digitoxin, but is probably more
widely used in most regions in the country. There also
appears to be a general decline in the intravenous use of
Cedilanid and ouabain.
The benefits and risks of concomitant use ofdigitalis and
quinidine have been debatedfor decades. In 1956, Friedberg
(I) stated that' 'most physicians avoid simultaneous use of
digitalis and quinidine because of a possible dangerous po-
tentiating effect but there is no reliable clinical evidence to
support this taboo. " The desired evidence appeared, at least
for digoxin, when it was shown that serum digoxin con-
centration more than doubled during quinidine therapy (14).
It is unclear whether this effect is due to the displacement
of digoxin from binding sites by quinidine (15,16) or to the
decrease of renal clearance of digoxin by quinidine (17), or
to both (18). Although it is not certain that increased plasma
digoxin concentration causes toxicity or reflects increased
myocardial concentration of the drug, it has been reported
(14) that reduction of the digoxin dose while maintaining
the same dose of quinidine eliminates nausea and vomiting
attributed to digitalis toxicity. The distribution and clearance
of digitoxin, unlike those of digoxin, are not changed by
quinidine (19).
Procainamide. Despite a large incidence of adverse ef-
fects during its prolonged administration (20), procainamide
has remained one of the most widely used drugs for treat-
ment and prophylaxis of ventricular arrhythmias. The most
serious toxic effect of its prolonged administration is the
induction of a systemic lupus erythematosus-like syndrome,
first described by Ladd (21) in 1962. Patients with this
syndrome have antibody to denaturated deoxyribonucleic
acid (DNA) but, unlike patients with idiopathic systemic
lupus erythematosus, little or no antibody to native DNA
(22). Both the symptoms and the antibody usually disappear
when administration of the drug is discontinued. The major
metabolite of procainamide, N-acetylprocainamide (NAPA),
does not induce a lupus-like syndrome (23). The electro-
physiologic characteristics of NAPA are somewhat different
from those of procainamide, and there is no agreement about
the antiarrhythmic potency of NAPA generated by the me-
tabolism of procainamide or administered as a separate com-
pound (acecamide). In one study (23), NAPA suppressed
ventricular ectopic complexes in several patients. However,
in another study (24) of patients treated for chronic ven-
tricular tachycardia with procainamide, the suppression of
arrhythmia correlated poorly with NAPA concentrations.
Measurement ofplasma procainamide concentrations may
be useful in monitoring therapy aimed at maintaining an
effective plasma concentration, usually within the range of
8 to 16 mg/liter (25,26). A 3 hour dosage was recommended
to maintain such concentrations. However. a sustained-re-
lease preparation obviates this difficulty and maintains ad-
equate plasma drug concentrations using an 8 hour dosage
(27). Procainamide is one of the most frequently tested drugs
used routinely during studies of inducibility of ventricular
tachycardia in the electrophysiology laboratory. In one such
study (24), the drug prevented induction of ventricular
tachycardia or fibrillation in 74% (16 of 25 patients) of those
who could be successfully treated with drugs. Such suc-
cessful prophylaxis may require larger than conventional
doses (5 to 6 g [28] or 3 to 9 g [24] per day).
Quinidine. The status of quinidine has not changed ap-
preciably during the past 25 years. although the knowledge
of quinidine-induced syncope caused by ventricular fibril-
lation or torsade de pointes has become more widespread
because of the increased utilization of ambulatory electro-
cardiographic monitoring. These arrhythmias are not de-
pendent on a critical plasma drug concentration (29-32),
and can occur after administration of other quinidine-like
drugs and amiodarone. The availability of long-acting prep-
arations such as quinidine gluconate makes it possible to
maintain plasma quinidine concentration using a 12 hour
dosage schedule (33).
368 J AM COLL CARDIOL
1983;I:365-81
SURAW1CZ
Potassium. It has been known for more than 25 years
that potassium salts administered intravenously suppress
supraventricular and ventricular ectopic complexes and
rhythms in approximately 80% of patients independent of
initial plasma potassium concentration, presence or absence
of heart disease and digitalis therapy (34). However, in the
absence of hypokalemia and digitalis toxicity, the thera-
peutic effect is usually transient, being dependent on the
rate of administration rather than on absolute plasma po-
tassium concentration. This therapy also requires close mon-
itoring because of the narrow margin between therapeutic
and toxic concentrations of plasma potassium. Therefore,
in practice, rapid intravenous administration of small doses
of potassium salts is most useful for treatment of arrhythmias
related to potassium deficiency, such as postoperative ar-
rhythmias (35), hypokalemia or digitalis toxicity. There has
been no change in the recommendation for oral potassium
supplements to prevent and treat arrhythmias in patients
treated with digitalis and thiazide diuretic drugs (36).
Passing Fancies
Long before the discovery of calcium blocking agents, it
was known that hypocalcemia induced by administration of
disodium ethylenediamine tetraacetic acid (EDTA) sup-
pressed supraventricular and ventricular arrhythmias in about
50% of patients, and that the therapeutic efficacy in patients
treated and not treated with digitalis was equal (37). This
antiarrhythmic effect, attributed to prolongation of atrial and
ventricular refractory periods (37), was probably unrelated
to the possible slow channel blocking activity of hypocal-
cemia. The use of EDT A salts was a popular therapeutic
choice for only a short period of time and they are no longer
used for treatment of arrhythmias. Another transiently pop-
ular drug, the antihistamine antazoline, appeared to have
been effective when used intravenously or orally for treat-
ment of various types of ectopic rhythms (38,39).
New Approved Drugs
Beta-receptor and slow channel blocking agents. The
two most important additions to antiarrhythmic drug therapy
are the beta-receptor blocking agents, which have been used
for approximately 20 years, and the slow channel blocking
agents, available in this country for about 2 years. Both
types of drugs have in common slowing of conduction and
prolonging of refractoriness in the AV node, thus slowing
ventricular rate in patients with supraventricular tachycar-
dias, atrial fibrillation and atrial flutter (40--45). Because
both types of drugs have a negative inotropic effect, it is
frequently advantageous to administer them in combination
with digitalis, which has a positive inotropic effect. By
combining the synergistic effects of beta-receptor blocking
drugs, slow channel blockers and digitalis on the AV node,
smaller maintenance doses of digitalis can be administered
with avoidance of digitalis toxicity. The use of beta-receptor
blocking and slow channel blocking drugs in the treatment
of ventricular arrhythmias is limited to certain specific sit-
uations (see later).
Disopyramide. The choices of drugs for treatment of
chronic ventricular arrhythmias increased when disopyr-
amide was approved for general clinical use in the United
States in 1977. The electrophysiologic properties of this
drug are similar to those of quinidine and procainamide (46),
but the toxic extracardiac manifestations are primarily due
to its anticholinergic effects, in particular urinary retention,
dry mouth and blurred vision. Disopyramide is well ab-
sorbed, has a half-life elimination time of about 6 hours and
is usually administered in doses of 100 to 200 mg every 6
hours. The effective therapeutic serum concentrations range
from 2 to 5 mg/liter (47). At these concentrations, there
may be only a slight increase in QRS duration and prolon-
gation of the QT interval, but there are considerable indi-
vidual differences in the electrocardiograms. In analogy to
other so-called class I antiarrhythmic drugs (48), disopyr-
amide may produce adverse hemodynamic effects, depress
sinus node function and cause serious ventricular arrhyth-
mias, usually a polymorphic tachycardia associated with QT
prolongation (49).
Lidocaine. Lidocaine should also be mentioned in the
context of the new drugs because it has been used by car-
diologists for less than 25 years. The extraordinary thera-
peutic effectiveness and the absence of serious undesirable
hemodynamic and electrocardiographic effects have made
monitored intravenous therapy with lidocaine a nearly uni-
versally accepted method of choice for the treatment of most
types of serious ventricular arrhythmias in the hospital, and
particularly in coronary care units (50-53).
What Happened to Therapeutic Goals of
25 Years Ago?
The broad goals of therapy-prolonging life, preventing
serious complications, alleviating discomfort and improving
life style-have remained unchanged. However, the in-
creased knowledge of the natural history of arrhythmias, an
understanding of their clinical significance and progress in
therapy have resulted in a more rational and selective ap-
proach to prevention of sudden cardiac death in patients in
several high risk categories, including acute myocardial
ischemia, ventricular aneurysm and arrhythmias associated
with prolonged QT interval (54,55).
The effectiveness of lidocaine prophylaxis for prevention
ofprimary ventricular fibrillation in the pre-hospital phase
of myocardial infarction has been a subject of controversy.
However, recent controlled studies seem to vindicate the
views of the early proponents (56) by showing that lidocaine
prophylaxis significantly reduces the prevalence of primary
ventricular fibrillation in patients admitted to coronary care
units (57-59). A more difficult problem that requires res-
olution is the approach to prophylactic therapy of ventricular
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arrhythmias in high risk candidates for sudden cardiac death .
These candidates include survivors of primary ventricular
fibrillation who have never had acute myocardial infarction
(60) and patients who have ventricular tachycardia after
recovery from myocardial infarction (61,62). The effec-
tiveness of antiarrhythmic drug therapy in these patients
needs to be established. It is also important to determine
whether an effective prophylaxis consists of suppression of
most ventricular premature complexes or merely suppres-
sion of repetitive ventricular rhythms without suppression
of such complexes (63).
Will Any of the New. Currently Tested Experimental
Drugs Become Superior to the Established Approved
Antiarrhythmic Drugs?
A better drug can be expected to offer a new and different
mode of action, a new combination of known antiarrhythmic
properties or a wider margin between therapeutic and toxic
doses. When these criteria are applied. currently tested ex-
perimental drugs do not appear to be superior to the ap-
proved drugs with similar actions .
Aprindine has local anesthetic effects and quinidine-like
electrophysiologic properties , but it shortens action potential
duration in the Purkinje fibers and prolongs refractory period
of the atrioventricular node (64). The drug is capable of
preventing recurrent ventricular tachycardia and ventricular
fibrillation (65) but can cause prolongation of QT interval,
polymorphous ventricular tachycardia. syncope (66). cho-
lestatic jaundice and agranulocytosis .
Encainide has quinidine-like properties and causes pro-
longation of QRS and QT intervals as well as of conduction
in the atrioventricular node (67.68) . The drug is effective
in treatment of both supraventricular and ventricular ar-
rhythmias (69), but it may also worsen ventricular arrhyth-
mias and induce "malignant ventricular tachyarrhythmias"
(70).
Flecainide appears to have quinidine-like properties. and
prolongs QRS, QT and PR intervals and suppresses ven-
tricular ectopic activity (71) . The drug has a relatively long
elimination half-life and can be administered twice daily
(71). Drug-induced ventricular tachycardia has been re-
ported (72).
Lorcainide and pirmenol are two new drugs with local
anesthetic properties and quinidine-like action (73.74). Lor-
cainide administered twice daily effectively suppressed ven-
tricular tachyarrhythmias. and the adverse effects appeared
tolerable (75).
Mexiletine is structurally similar to lidocaine (76.77) but
causes prolongation of the QRS complex (78) . Mexiletine
suppresses ventricular arrhythmias during acute myocardial
infarction. but whether it is as potent as the parenterally
administered lidocaine is uncertain (79) .
Tocainide is also a lidocaine-like drug (80) that can be
administered orally once or twice daily (81). The toxic ef-
fects on the central nervous system are similar to those of
lidocaine (81).
How Useful Is Classification of
Antiarrhythmic Drugs?
The proliferation of new antiarrhythmic drugs makes it nearly
impossible to retain the information regarding their different
characteristics and to remember the particular drug prop-
erties that correspond to similarly named compounds cited
in the published reports. Therefore, some type of classifi-
cation is necessary for categorizing drug actions and com-
paring new drugs with the familiar prototypes. The most
popular classification is that of Vaughan Williams (48), who
proposed a subdivision into four main classes of drugs: those
that decrease the upstroke velocity of the rapid channel-
dependent action potential (class I), those that predomi-
nantly affect the autonomic nervous system, for example,
beta-adrenergic blocking drugs (class lJ), those that prolong
action potential duration but have little effect on its upstroke
velocity. such as bretylium tosylate or amiodarone (class
III) and those that affect the central nervous system (class
IV). The slow channel blocking drugs would constitute an
additional class in this type of scheme. As pointed out by
Gettes (82), the two distinct groups of drugs within the class
I grouping of Vaughan Williams, the quinidine-like and the
lidocaine-like drugs, are sufficiently dissimilar in mecha-
nism to warrant assignment to separate categories.
Thus, a more modern scheme would recognize the fol-
lowing five main classes: I) quinidine-like drugs. which
prolong the QRS interval and usually the QT interval also;
2) lidocaine-like drugs, which cause no discernible electro-
cardiographic changes because they have negligible effect
on fibers with normal resting membrane potential; 3) slow
channel blocking drugs; 4) beta-adrenergic blocking drugs;
and 5) miscellaneous drugs that have no consistent effect
on the QRS complex but may prolong the QT interval (arnio-
darone and perhaps bretylium). This classification attempt
shares many faults and inconsistencies with previous at-
tempts because it does not consider the various electro-
physiologic properties that exist in addition to those singled
out for the purpose of classification. These additional prop-
erties vary in prevalence and intensity among different drugs
and overlap within different classes of drugs. Even if a more
systematic and electrophysiologically accurate classification
were developed, its impact would probably not alter the
validity of Gettes' statement (82) that no classification "al-
lows the physician to predict with any consistency the effect
of one drug or group of drugs in treating a specific
arrhythmia..,
The probable usefulness ofany new antiarrhythmic drug
will depend on several properties that are only, in part,
related to the cellular mechanism of action. In Table I. I
have outlined some questions that may be relevant to the
predicted clinical efficacy of a new drug.
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Table I , Some Questions Concerning a New
Antiarrh ythm ic Drug
Structure
Route of administration
Absorption, disposition. eliminatiun
Therapeutic-toxic margin
Interaction with other drugs
Activity of metabolites
Mode of action
Vagal
Beta-adrenergic
Alpha-adrenergic
Rapid channel
Rate dependence
Voltage dependence
Slow channel
Potassium conductance
Effect on basic properties
Automaticity
Excitability
Refractoriness
Relation between duration of action potential and refractoriness
Conduction in different portions of thc heart
Other effects
Inotropic
Sodium. potassium. membrane adenosine triphosphatase
Toxicity
Short-term
Long-term
Specific: crossing thc placenta
Contributions of Cellular Electrophysiology
to the Understanding of Drug Action
Quinidine-like Drugs
Action on rapid inward sodium channel. More than 25 year s
ago. Weidmann (83) found that the local anesthetic drugs exhib-
iting antiarrhythmic properties do not change the resting membrane
potential but inhibit the influx of sodium ions (Na +) through the
rap id channel during depolarization of cardiac fibers. These drugs
interfere with the "sodium-carrying" mech anism so that at each
level of membrane potentia!. the rapid inward Na + current (iN'>
is less than the control current. Figure I shows a plot. known as
membrane responsivene ss . describ ing the relati on between the
membrane potential on the abscissa , and the Vrnax of the action
potenti al upstroke (an assumed measure of the iNa) on the ordinate .
In this figure . the membrane potenti al range s from the threshold
of activat ion (approximately -55 to about - 120 mY). How-
ever . it can be seen that Vrnax is maximum at about - 85 mY
and docs not get larger with further increase of membrane potent ial ,
that is. hyperpolarization to - 100 or - 120 mY. The flat curve
that falls with in this potential rang e shows that the Vmax has
reached the level of the max imal ava ilable Na + condu ctance of
the channel (gNa)' It was first shown by Weidmann, and later
confirm ed by many investigators, that a local anesthetic, cocaine .
and many ant iarrhythmic drugs that depre ss the " Na + carrying"
system shift the responsiveness curv e both to the right and down-
ward (Fig . I). Because Vmax repre sent s one of the most important
determin ants of conduction veloci ty. a right ward shift of the mem-
brane responsiveness curve means that at eac h level of membrane
potent ial . the impulse propagation is slower than control. The
reduction of Vrnax in incompletely repolarized fibers. that is. in
premature impulses ari sing during phase 3 of the preceding action
potential or in impul ses initiated durin g diastolic depolarization
(phase 4 ). may be considered an antiarrhythmic property because
propagation is more difficult within depolarized or incompl etely
repolarized cardiac tissue .
When the membrane responsiveness C111'1'e is shifted downward,
that is. the gNa is depressed . the impulse propagation in fibers at
norm al resting membrane potent ials is slower than contro l. Th is
is clinically manifested by dose-dependent widening of the P waves.
the HY intervals or the QRS complexes produced by quinidine.
procainamide, disopyramide and other drugs with similar action .
Figure I also shows that the rightward shift of the responsive-
ness curve is associated with a rightw ard shift of the threshold
potent ial for the activation of the iNa. A more negative threshold
potenti al means that the earliest possible premature impulse will
occur later during phase 3 and that the latest premature impulse
will occur earlier durin g phase 4 . narrowing the time zone available
for the occurrence of propagated premature impulses in depolarized
myocardium . Becau se conduction and excitability are closely in-
terrelated , most drugs that depress conduction cause parallel changes
in excitability . Thi s means that at any given level of membrane
potent ial . a decrease in Vmax is usually assoc iated with a decrease
in exc itability . that is. the necessity of deli vering a current pulse
of greater strength or longer duration to evo ke a propagated im-
pulse. Thus. a shift of the membrane responsiveness curve to the
right is usuall y accompanied by a shift of the strength-interval
curve to the right. Thi s curve is constr ucted by plottin g either the
interval betwe en stimuli or the diastol ic (coupling) interval on the
abscissa and plott ing the strength of the stimulus required to elicit
a propagated response on the ordinate.
Depression of normal automaticity and prolongation of ac-
tion potential. In addition to the depression of rapid iNa. two other
properties of the quinidine-like drugs may contribute to their an-
tiarrhythmic action. One of these is the depression of normal au-
tomati city dependent on the pacemaker current. which until re-
cently had been considered as potassium ion (K +) current (iK~) .
but has now become subject to other interpretations (84), The othe r
property is the prolongation of action potenti al duration. which
may be expected to prolong the refractorin ess. The prolon gation
of action potenti al in the ventricular myocardium result s in the
prolongation of the QT interval (corrected for both the QRS du-
rat ion and rate ). and fusion of T and U waves . To be of potent ial
benefit . the prolongation of action potentia l duration should be I)
uniform (that is. cause no increase in the dispersion of repolari-
zation). and 2) confined to the absolute refractory period (that is .
the port ion of repolarization that is more negative than the threshold
potenti al for acti vation of iNa)' Whether the first requirement is
fulfilled has not been sys tematica lly inves tigated; howe ver . there
is no particular reason to suspect that the drugs increase the non-
homogeneity of repol arizat ion in the normal myocardium.
The second requ irement is probably not fulfilled becau se quin-
idine-like drug s prolong the term inal phase of repolarization. which
includes the segment betwe en the threshold potential and the rest-
ing potential. The prolonged duration of this segment mean s that
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Figure 1. Relation between membrane "clamp"
potential and maximal rate of rise of action poten-
tial in a sheep Purkinje fiber in the absence (normal
Tyrode solution) and in the presence of cocaine.
Discussion in text. (Reprinted from Weidmann S
[83], with pennission.)
the relative refractory period at the cellular level is prolonged. It
is expected that this would prolong the duration of the refractory
period at the tissue level, widening the time zone available for
propagation of premature impulses at reduced velocity. These ac-
tions explain the two potentially contrasting consequences of the
drug-induced prolongation of the QT interval: the potentially ben-
eficial effects of the prolonged effective refractory period and the
potentially deleterious effects of the prolonged relative refractory
period.
These considerations indicate the difficulty in predicting the
influence of various electrophysiologic alterations on the clinical
arrhythmias. Depressed conduction and excitability may result in
narrowing of the' 'extrasystolic zone," while prolongation of the
relative refractory period may widen the "extrasystolic zone."
The former property can be antiarrhythmic, and the latter arrhyth-
mogenic. Similarly, depressed automaticity of the ectopic pace-
makers may be anitarrhythmic, or deleterious, if it suppresses the
escape pacemakers.
Effect on kinetic properties of sodium channel. So far. I
have limited my discussion to the voltage-dependent aspects of
the quinidine-like drug action on the rapid inward sodium channel.
However, electrophysiologists have long known that these drugs
also alter the kinetic properties of the sodium channel because the
depression of Vmax by quinidine increases when the rate of stim-
ulation is increased (85,86). Electrocardiographers are also aware
of the time-dependent effect of quinidine on conduction. For in-
stance, the electrocardiogram in Figure 2 shows that after long RR
intervals, the QRS complex is narrower than after short RR in-
tervals. This cannot be a result of either the differences in the
membrane potential during phase 3 because QRS complexes of
VI
Figure 2. A,Time-dependent effects of quinidine treat-
ment on the electrocardiogram. During quinidine therapy.
the QRS complex is wider when the rate is rapid. The
QRS complex is also wider in the premature complexes
with shorter coupling intervals than in those with longer
coupling intervals. B, Control tracing without quinidine.
(Published with permission of Charles Fisch. MD, Indi-
anapolis, Indiana.)
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Figure 3. Effect of lidocaine, 8 /-Lg/ml, on the recovery
of dV/dt (max) in guinea pig papillary muscle when the
resting membrane potential was - 90 and -79 mV (de-
polarization by potassium). The arrows show the time
constantof the restitution of the premature action potential
duration to the steady state value (not shown). The insert
shows the methodof stimulation at various test intervals.
Discussion in text. (Reprintedfrom ChenCM, Genes LS,
Katzung BG [88], with permission.)
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unequal duration are not premature, or of diastolic depolarization
during phase 4 because quinidine suppresses the diastolic depo-
larization in the Purkinje fibers. The differences in the QRS du-
ration must be attributed to differences in timing, independent of
membrane potential, that is, drug effect on the kinetic properties
of the sodium channel.
Under normal conditions, the activation, inactivation and re-
covery from inactivation of the sodium channel occur rapidly (87),
and recovery is complete when repolarization ends. However,
the sodium channel blocking drugs slow recovery from inactivation
(88) and delay the repriming of the system beyond the end of
repolarization. This means that an earlier premature impulse elic-
ited after the end of action potential will be conducted more slowly
than will a later premature impulse. An additional complexity
arises from the observations that the time-dependent recovery of
Ymax is altered not only by the immediately preceding diastolic
interval, but also by the more distant past history of stimulation.
It has been shown that the increased rate of stimulation enhances
the capacity of the drug to depress the sodium current (89). This
frequency-dependent depression of sodium current is also known
as the use-dependent depression (90), a term adapted from nerve
pharmacology (91). In the nerve, the use-dependent block is at-
tributed to the binding of drugs to open channels (9 I). This hy-
pothesis proposes that the sodium current is inactivated temporarily
in those channels that are blocked by the drug, but not in the
unblocked channels, making this mechanism of depression dif-
ferent from the drug-induced increase in inactivation during steady
state (83) or from the prolonged recovery from inactivation (88,92).
In practice, the difference between the time-dependent effect and
the use-dependent effect can be shown by comparing the time-
dependent effect of a single extrasystole with that of a heart rate
at the same cycle length as the coupling interval of the same
extrasystole. The use-dependence induced by drugs is probably of
great importance in determining the effects of this type of antiar-
rhythmic agent because at each level of membrane potential, their
effect on conduction will be determined not only by the prema-
turity, but also by the heart rate and the sequence of RR intervals.
Further analysis of the effects of drugs on the rapid sodium
channel reveals that both the time-dependence and the use-de-
pendence are voltage-dependent processes. Even under normal
conditions, the recovery from inactivation of the rapid Na + channel
is slower in depolarized myocardium than at normal resting mem-
brane potential (92). These membrane potential-dependent differ-
ences can be augmented appreciably by the antiarrhythmic drugs
blocking the rapid Na + channel. Figure 3 shows that lidocaine
slows the recovery of Ymax compared with the control, and that
this slowing is greater in the depolarized myocardium than at the
normal resting membrane potential. Other sodium channel block-
ing drugs produce similar effects on the recovery from inactivation
and also on the use-dependence of the sodium channel.
Lidocaine-like Drugs
These observations help explain the antiarrhythmic action of a
drug like lidocaine that blocks the iNa (93-95) but causes no
clinically manifest depression of conduction as determined by the
unchanged durations of the P waves and HV and QRS intervals.
Although lidocaine depresses the voltage-, time- and use-depen-
dent kinetic properties of the sodium channel and shifts the mern-
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Figure 4. Effect of lidocaine on membrane responsiveness of blood-su-
perfused canine Purkinje fiber. Abscissa: membrane potential at which the
action potential was initiated; ordinate: Ymax of phase O. Lidocaine was
infused to the donor dog. After 113 minutes, membrane responsiveness
(broken line) wasdepressed, butthedepression wasgreater at lessnegative
thanat more negative membrane potential. Discussion in text. (Reprinted
from Rosen MR, Hoffman SF, Wit AL [93], with permission.)
brane responsiveness curve to the right. it has little effect on gNa'
Figure 4 shows the drug effect on the membrane responsiveness
curve in dog Purkinje fiber. It can be seen that the difference in
Vmax between control and lidocaine is much smaller at the level
of -82 mYthan at the level of -70 mY. These membrane potential
differences are even more pronounced in the ventricular muscle
fibers (88). Figure 3 shows that after a long test interval, Ymax
is more depressed at the level of -79 mY than at the level of -90
mY. This difference can be explained by a greater shift of the
responsiveness curve to the right at the level of -79 mY than at
the level of -90 mY. These effects are different from those of
quinidine in the same preparation. Figure 5 in reference 88 shows
that quinidine depresses Vmax equally at the level of -85 and
-70 mY (88), because the shift of the responsiveness curve to the
right is associated with a considerable decrease in gNa.
A discussion of lidocaine is not complete without mentioning
that this drug depresses the pacemaker current responsible for the
diastolic depolarization in the Purkinje fibers (94,95). The clinical
relevance of this effect is uncertain, because in most patients with
AY block, therapeutic lidocaine concentrations have little effect
on the automaticity of escape pacemakers, both proximal and distal
to the His bundle (96,97).
Effect on conduction. As may be presumed from the voltage-
and time-dependent effects of lidocaine on iNa' the drug has a
greater depressing effect on conduction in diseased and presumably
Clinical Implications
Drugs that depress conduction. Until now. I have dis-
cussed those properties of the quinidine-like and lidocaine-
like drugs that may be expected to increase myocardial
depression, an action that could extinguish slowly propa-
gating impulses and, perhaps, induce bidirectional conduc-
tion block within areas of reentrant activity caused by a
preexisting unidirectional block. These depressing drug
properties have included a shift of the membrane respon-
siveness curve to the right; decreased gNa; increased time
interval between the end of action potential and the recovery
of excitability, that is. shift of strength-interval curve along
the time axis due to delayed recovery of iNa from inacti-
vation; decreased excitability due to decreased membrane
responsiveness; increased use-dependence of the rapid Na +
channel; and augmentation of slow iNa recovery from in-
activation and of the use dependence by depolarization.
Many of these properties vary among drugs acting on
the rapid inward sodium channel, presumably because of
differences in the time- and voltage-dependent interactions
between the drug and the channel. It has been assumed that
antiarrhythmic drugs can interact with the sodium channel
in the resting. activated and inactivated states and that each
drug exerts a characteristic effect on the association and
dissociation rate constants for the interaction with the chan-
nel (90). When these factors are incorporated into a mo-
lecular model of the drug action. the model simulates the
actions of quinidine and lidocaine at various rates, rhythms
and levels of membrane potential satisfactorily (90). It re-
mains to be seen whether the model in the present or mod-
ified form (03) will be helpful in understanding the drug
action and in developing new antiarrhythmic drugs that act
on the rapid inward sodium current.
Drugs that restore excitability and conduction.
Current opinion attributes the antiarrhythmic action of the
sodium channel blocking drugs to depression of conduction.
depolarized regions than in normal myocardium (98-10 I). We
may also expect that lidocaine will depress conduction more at
fast rates and after short pauses than at slow rates and after long
pauses.
Effects in acute ischemia and infarction. Clinical observa-
tions suggest that lidocaine is particularly effective in suppressing
ventricular tachyarrhythmias in patients with recent myocardial
infarction and acute myocardial ischemia. However. in patients
with ventricular tachycardia associated with ventricular aneurysm,
the inducibility of arrhythmia is more often prevented by procain-
amide or other quinidine-like drugs (1021. It is tempting' to spec-
ulate that in the setting of acute ischemia. a drug can abolish
arrhythmia by suppressing conduction in the depolarized ischemic
myocardium, but that to inhibit arrhythmia arising at the border
zone between damaged and normal myocardium near a ventricular
aneurysm. the drug must be capable of depressing conduction in
both the normal and the depolarized myocardium.
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Older. less popular notions that lidocaine-like drugs may
improve conduction by shortening action potential or de-
creasing dispersion of repolarization cannot be dismissed
entirely from consideration (see references in 93). We do
not know whether any of the antiarrhythmic drugs act by
restoring a more normal excitability and conduction within
the arrhythmogenic focus. Such an effect can be accom-
plished by means of hyperpolarization of partially depolar-
ized fibers that may be caused, for example, by hypoka-
lemia, digitalis, stretch and various other factors (see
references in 104). Hyperpolarization can be induced by
increasing the rate of pacing, administering catecholamines
or acetylcholine and using other methods to suppress dia-
stolic depolarization. In practice. such events may occur
during various acute interventions, such as during treatment
of digitalis toxicity with potassium, administration of iso-
proterenol for treatment of bradycardia-related ventricular
arrhythmias and use of catecholamines in the process of
cardiac resuscitation. It is also possible that in some cases
the beneficial effects of chronic antiarrhythmic therapy with
quinidine-like, lidocaine-like, beta-adrenergic blocking, slow
channel blocking or unclassified drugs such as bretylium or
amiodarone are due to suppression of diastolic depolariza-
tion or to hyperpolarization of depressed fibers. At this time
it appears difficult, if not impossible, to dissect and docu-
ment the role of these mechanisms in clinical practice.
Another possible means of improving conduction would
be to "enhance" membrane responsiveness, that is, pre-
cipitate an increase in Vrnax at any given level of membrane
potential, which would shift the membrane responsiveness
curve to the left and upward. Such an effect was initially
attributed to phenytoin in canine Purkinje fibers (105). How-
ever. the enhanced responsiveness (Fig. 8 in reference 105)
was found only in partially depolarized fibers or in fibers
with normal resting membrane potential but "low rates of
depolarization" (105). Some evidence for "enhanced" con-
duction by phenytoin has been obtained in clinical studies
in which the drug shortened the HV interval and improved
conduction in patients with intraventricular conduction dis-
turbances (106,107).
In the clinical setting, the mechanism of the apparent
improvement in conduction cannot be precisely determined.
In the case of phenytoin, a shortening of HV interval could
have occurred in the absence of any changes in "membrane
responsiveness" due to depression of phase 4 or shorter
action potential duration (105), or both, resulting in a shorter
refractory period.
Phenytoin. Because of the assumed differences between
the effect ofphenytoin and quinidine-like drugs on the rapid
sodium channel, phenytoin was presumed to provide some
insight into the mechanism of arrhythmias. The drug ap-
peared to be particularly useful in the treatment of arrhyth-
mias caused by digitalis toxicity. Orally administered phe-
nytoin was found to be effective in controlling certain
ventricular and supraventricular arrhythmias resistant to
conventional therapy (108) and in treating postoperative
ventricular arrhythmias (109). Nevertheless, it is of limited
use today because it has failed the crucial tests of preventing
recurring ventricular tachycardia due to coronary artery dis-
ease (110) and of inhibiting inducibility of ventriculartachy-
cardia in the majority of tested patients (102).
It also appears doubtful whether the principal mode of
action of phenytoin differs from that of other drugs that
depress sodium conductance through the rapid channel. In
appropriate concentrations. phenytoin decreases membrane
responsiveness. increases the interval between the end of
action potential and the onset of excitability (induction of
time-dependent refractoriness) (111,112) and has a more
pronounced depressing effect on depolarized than on normal
fibers (112).
Drugs that affect duration of action potential (QT
interval). The effect of antiarrhythmic drugs on the dura-
tion of cardiac action potential is important because- under
normal circumstances (normal resting membrane potential),
this duration determines how long effective refractory pe-
riods last in all cardiac fibers outside the sinoatrial and AV
nodes. In the latter, depolarization depends on slow channel
activity and refractoriness is less dependent on action po-
tential duration.
Often, the effects ofa drug on the duration of ventricular
action potential can be deduced from their effect on the
duration of the QT interval on the electrocardiogram. Drugs
with quinidine-like action (disopyramide, encainide, fle-
cainide, lorcainide, procainamide and quinidine, for ex-
ample) prolong the duration of both the ventricular action
potential and the QT interval. Several antiarrhythmic drugs
acting on the rapid sodium channel shorten the duration of
cardiac action potential in the tissue bath, in particular in
the Purkinje fibers. This category includes phenytoin. li-
docaine and lidocaine-like drugs (tocainide, mexiletine, for
example). Clinically. these drugs produce no recognizable
shortening of the QT interval, probably because the con-
centrations achieved in clinical practice do not cause a sig-
nificant shortening of the ventricular action potential. Clin-
ical observations suggest that the antiarrhythmic effectiveness
and potency cannot be predicted from the presence, absence
or magnitude of QT prolongation. This indicates that the
antiarrhythmic effectiveness cannot be predicted from the
changes in duration of cardiac action potential, an action
determined by variable effects of these drugs on the plateau
currents (113). However. this does not imply that changes
in refractoriness playa subordinate role in the genesis and
maintenance of ventricular arrhythmias. Such a conclusion
would be contrary to the wealth of experimental and clinical
data concerning the arrhythmogenic role of the dispersion
of refractoriness.
Effect on dispersion of refractoriness. The effect of
antiarrhythmic drugs on dispersion of refractoriness may be
more important than that on the absolute value of refrac-
toriness. One location within the heart where the effect of
DRUG TREATMENT OF ARRHYTHMIAS J AM CaLL CARDIOL
1983; 1:365-81
375
drugs on dispersion has been studied is the portion of the
conduction system extending from the His bundle to the
Purkinje-papillary muscle junction. Within this portion, the
duration of cardiac action potential continuously changes
by first becoming progressively longer, reaching a certain
maximum (known as gate [114]) and then declining pro-
gressively as it moves toward the Purkinje-papillary muscle
junction. Several antiarrhythmic drugs, including lidocaine
(93) and disopyramide (46), have been shown to decrease
the inherent action potential duration differences within this
portion of the heart. However, the refractoriness in this
region may not be crucial to the genesis or maintenance of
serious ventricular tachyarrhythmias originating within the
diseased myocardium in patients with coronary or other
organic heart disease. In the appropriate animal models,
antiarrhythmic drugs have been reported to decrease dis-
persion of refractoriness between healthy and damaged myo-
cardium (115,116), but the possible role of these assumed
beneficial effects on refractoriness cannot be dissociated
from the concomitant drug-induced changes in excitability
and conduction that vary with the underlying levels of mem-
brane potential and the activation sequence.
The slow channel blocking drugs. The introduction of
slow channel blocking drugs has provided therapeutic op-
tions that could be anticipated accurately from the anteced-
ent experimental, physiologic and pharmacologic studies in
vitro. The therapeutic concentrations of these drugs do not
block the rapid inward iNa (117), and have no effect on
conduction and refractoriness in the atria, His-Purkinje and
ventricular myocardium or on the automaticity of pace-
makers outside the sinoatrial and AV nodes (118). Thus,
the occasional effectiveness of these drugs in treating ar-
rhythmias that originate outside the domain of slow channel-
dependent activity is probably due to an indirect action,
such as relief of myocardial ischemia (119,120). Other prob-
lems complicating the assessment of the antiarrhythmic ac-
tion of the slow channel blocking drugs are that they affect
conductance through other channels, such as time-depen-
dent and time-independent outward currents (121), and that
these effects may alter the electrophysiologic and antiar-
rhythmic properties of the drugs (122).
Beta-receptor blocking drugs. The preceding discus-
sion has focused on the role of sodium channel blocking
drugs in the treatment of ventricular arrhythmias. I have
also suggested that the depression of normal automaticity
by both the quinidine-like and the lidocaine-like drugs may
contribute to suppression of those arrhythmias that are due
to increased automaticity or to slow conduction during di-
astolic depolarization. A similar mode of action may be
suspected in the case of beta-receptor blocking drugs when
they suppress exercise-induced (123,124) and nonexercise-
induced ventricular arrhythmias (125). However. propran-
olol and other beta-receptor blocking drugs have a quinidine-
like effect on the rapid iNa (75,126) as well. This effect may
be of greater importance than the beta-receptor blocking
action, because the plasma propranolol concentrations as-
sociated with suppression of ventricular arrhythmias tend to
be higher than those required to achieve a substantial level
of beta-adrenergic blockade (125). In analogy to lidocaine
and other rapid sodium channel blocking drugs, propranolol
depresses conduction and prolongs refractoriness more in
the ischemic than in the nonischemic zone after coronary
artery ligation in dogs (127).
Bretylium. Equally interesting is that ventricular ar-
rhythmias are sometimes suppressed by drugs that have little
or no suppressing effect, either on the rapid sodium channel
or on normal automaticity. Two examples of such drugs are
bretylium and amiodarone.
Bretylium tosylate has a reputation for effectively sup-
pressing life-threatening ventricular arrhythmias that are
refractory to all other drugs (128-130). According to Koch-
Weser (130), "in direct defibrillatory capability and ability
to facilitate electrical defibrillation, bretylium may well be
superior to other drugs." This antifibrillatory activity could
not have been predicted from the pharmacologic (130) and
the electrophysiologic (131) properties of the drug. Brety-
lium first releases norepinephrine from adrenergic nerve
endings (an action responsible for the positive inotropic
effect of the drug), subsequently inhibits norepinephrine
release by the action potential from adrenergic nerves and
finally blocks the uptake of norepinephrine and epinephrine
into adrenergic nerve endings (130). In single canine Pur-
kinje and ventricular fibers, bretylium does not suppress
diastolic depolarization or spontaneous automaticity in the
Purkinje fibers and has no effect on Vrnax. The drug pro-
longs the duration of cardiac action potential (an effect not
recognizable on the electrocardiogram), but does not change
the time relation between the effective refractory period and
the action potential duration (131). Bigger and Jaffe (131)
have speculated that the antiarrhythmic effect of bretylium
is due not to the action on the cell membrane, but to some
indirect action on adrenergic nerve terminals. The possible
beneficial effects of such action could derive from decreased
dispersion of action potential duration and hyperpolarization
(132).
Amiodarone. No less puzzling is the antiarrhythmic ef-
ficacy of orally administered amiodarone. The drug prolongs
conduction in the AV node, as well as the durations of
action potential in the atria, Purkinje fibers and ventricles.
The effect on the AV node may represent a slow channel
blocking action, although the drug also has beta-adrenergic
properties. A depressing effect on iNa is probably also present.
Amiodarone has attracted the attention of clinicians and
pharmacologists because 1) it is frequently effective in su-
praventicular and ventricular arrhythmias resistant to all other
drugs; 2) the onset and the offset of its action are very slow;
and 3) cardiotoxicity is uncommon even after administration
of large doses (that is, there is a relatively wide margin
between therapeutic and toxic doses) (133,134).
Amiodarone is considered a drug ofchoice for treatment
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of refractory arrhythmias associated with atrioventricular
bypass tracts (135,136). This may be due to the unique
properties of amiodarone, which prolongs AV nodal trans-
mission and the refractoriness of the His-Purkinje system,
atria, ventricles and AV bypass tract (a simultaneous effect
on five components of the reentrant circuit). Of additional
benefit may be the fact that prolongation of the refractory
period in the bypass tract occurs without slowing of con-
duction in this structure.
Amiodarone is the only tested antiarrhythmic drug that
significantly prolonged the refractory period in the acces-
sory pathway in patients in whom the inherent refractory
period of this pathway was less than 270 ms (137). In many
cases of refractory supraventricular and ventricular tachy-
cardia, the therapeutic efficacy of amiodarone may be due
to prolongation of refractory period in the myocardium and
His-Purkinje system. It will be of interest to determine whether
the prolongation of refractoriness and the QT interval is also
accompanied by a decreased dispersion of repolarization.
Antiarrhythmic Properties of Psychotropic Drugs
It should not come as a surprise that the drugs used to change
mood or behavior alter not only the electrical activity of the
brain cells and the autonomic nervous system but also the
ion fluxes across cell membranes in other excitable tissue,
including the heart. Phenothiazines, known to cardiologists
chiefly because of their alpha-adrenergic blocking proper-
ties. also have beta-adrenergic blocking (138) and local
anesthetic properties (139). In our study. both chlorprom-
azine and thioridazine induced dose-dependent decreases in
Vmax of the action potential during steady state, and quin-
idine-like effects on the recovery of iNa from inactivation
and on the duration of the action potential in canine Purkinje
and ventricular fibers (140) and in human atrial fibers (141).
Also, the phenothiazine derivative ethmozin, synthesized
in the Soviet Union, causes a dose-dependent decrease in
Vmax, but its shortening effect on action potential duration
is more similar to the action of lidocaine than of quinidine
(141). This drug can be used for suppression of supraven-
tricular and ventricular ectopic complexes (143.144). Also,
tricyclic antidepressants, imipramine. for example. have
quinidine-like electrophysiologic and antiarrhythmic prop-
erties (145).
Increased Availability
of Scientifically Verified, Accurate
and Detailed Information About the Role
of Drugs in Arrhythmias
Advances in basic sciences, rapid dissemination of new
knowledge, application of techniques developed in exper-
imental laboratories to study human subjects and progress
in instrumentation and computers probably have influenced
treatment of cardiac arrhythmias more than that of most
other medical conditions. As a result, today's physician can
assemble an overwhelming amount of information concern-
ing the relation between drugs and arrhythmias in a given
patient. Self-imposed restraint in seeking information is re-
quired by the limited ability to utilize such data and by cost
effectiveness. Nevertheless, some new investigative tech-
niques and methods of treatment are capable of resolving
many previously insoluble problems.
The following is a partial list of new developments and
concepts that have contributed to the progress in the treat-
ment of cardiac arrhythmias: 1) Improvement in the design
and accuracy of data collection, and in the reliability of
statistical analyses in studies of antiarrhythmic therapy. 2)
Better understanding of the therapeutic goals based on a
knowledge of the spontaneous variability of arrhythmias
(146-148). 3) Ability to assess electrophysiologic properties
relevant to the choice of treatment (for example. refractory
period of accessory pathway in patients with Wolff-Parkin-
son-White syndrome [137]), or the feasibility of studying
the effects of drugs on excitability, using strength-interval
curves (149,150) or ventricular fibrillation threshold mea-
surements in patients (151). 4) Excellent understanding of
the arrhythmia mechanism in most patients with supraven-
tricular tachycardia, making it possible to study the effects
of drugs on different components of the reentrant circuit
and to predict the therapeutic efficacy of propranolol (152),
ouabain (153), quinidine (154) or multiple drugs (155). 5)
Possibility of an occasional successful prediction of effec-
tive pharmacologic therapy in patients with symptomatic
ventricular tachycardias resistant to empiric therapy based
on inducibility of arrhythmia (156-159). 6) Use of the re-
sponse to drugs with known electrophysiologic propeities
to increase the understanding of the mechanism of arrhyth-
mia (154,160). 7) Greater impact of the study of pharma-
cokinetics (161), including consideration of absorption,
elimination kinetics and disposition, and the awareness of
the principal sites of degradation (for example, establish-
ment of inverse relation between hepatic blood flow and
levels of lidocaine [162]). The role of blood drug concen-
tration in decision making has been reviewed elsewhere
(163). Bigger (164) has summarized his recommendations
for testing drug blood levels as follows: a) to establish ther-
apeutic level of prophylaxis; b) to evaluate symptoms
suggestive of drug toxicity; c) to assess the effects of chang-
ing physiologic state or drug interactions; d) to detect in-
creased sensitivity or resistance; and e) to establish drug
compliance or drug abuse. 8) Importance of determining
the specific effects of drug metabolites that may modify the
effects of parent compounds, for example, NAPA level
measurements. 9) Better understanding of complex drug
interactions, such as that of quinidine with phenytoin (165).
The advances in basic and clinical pharmacology of an-
tiarrhythmic drugs have contributed to many beneficial mod-
ifications of therapeutic goals and principles. Some of these
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examples include: 1) the increased awareness that antiar-
rhythmic drugs may be arrhythmogenic (see references in
166-168); 2) therapy based on balancing the potential del-
eterious and beneficial effects of the same drug, for example.
negative inotropic effects versus slowing ventricular rate
when using propranolol in patients with acute myocardial
infarction (169); 3) the use of a combination of drugs with
similar mechanisms of action but different toxic extracardiac
manifestations, such as lidocaine and procainamide admin-
istered intravenously; 4) the use of a combination of drugs
with different mechanisms but similar sites of action, for
example, digitalis and propranolol (170) or digitalis with
verapamil to control the ventricular rate in patients with
atrial fibrillation; and 5) the use of a combination of drugs
with different mechanisms and different sites of action,
such as quinidine and propranolol to control ventricular
arrhythmia aggravated by sinus tachycardia.
Conclusions
Important advances in the pharmacologic treatment of car-
diac arrhythmias made during the past 25 years stem from
a substantial increase in our knowledge concerning the
mechanism of arrhythmias, the action of antiarrhythmic drugs
and the improved methodology of clinical investigation.
This progress appears to have benefited a greater proportion
of patients with supraventricular arrhythmias than with ven-
tricular arrhythmias. Several important problems. such as
defining the indications for treatment of asymptomatic and
mildly symptomatic ventricular arrhythmias, developing a
reliable antiarrhythmic drug with a wide margin of safety,
and preventing the electrical instability that causes sudden
death in persons with adequate mechanical function. have
not been resolved satisfactorily. However, the continuing
progress in basic and clinical research pertinent to these
problems augurs well for meaningful progress.
The escalating amount of new information about drugs,
electrophysiologic studies and clinical and epidemiologic
trials is taxing the physician' s capacity to absorb and classify
the incoming material to decide what may or may not be
relevant to practice. Despite these difficulties. the currently
available sophisticated methods of diagnosis and treatment
can resolve sometimes difficult and previously insoluble
problems in patients with disabling and life-threatening ar-
rhythmias. Today. the practitioner has many opportunities
to evaluate the results of individual therapy more accurately,
using stress testing, long-term electrocardiographic moni-
toring and electrophysiologic and pharmacokinetic studies.
In practice, the possible benefit of obtaining more accurate
information is counterbalanced by its very high cost in time
and money. Therefore. in the vast majority of patients.
antiarrhythmic drug therapy must rely predominantly on
prudent empiricism.
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